MARS2 — Mitochondrial Arginyl-tRNA Synthetase 2

MARS2 — Mitochondrial Arginyl-tRNA Synthetase 2

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">MARS2</th></tr>
<tr><td><b>Gene Symbol</b></td><td>MARS2</td></tr>
<tr><td><b>Full Name</b></td><td>Mitochondrial Arginyl-tRNA Synthetase 2</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>2q33.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[92935](https://www.ncbi.nlm.nih.gov/gene/92935)</td></tr>
<tr><td><b>OMIM</b></td><td>[609446](https://www.omim.org/entry/609446)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000135953</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9N3W4](https://www.uniprot.org/uniprot/Q9N3W4)</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Spastic Paraplegia (SPG74), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Parkinson's Disease](/diseases/parkinsons-disease), Mitochondrial Disorders</td></tr>
</table>
</div>

Overview

MARS2 — Mitochondrial Arginyl-tRNA Synthetase 2

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4ea;">MARS2</th></tr>
<tr><td><b>Gene Symbol</b></td><td>MARS2</td></tr>
<tr><td><b>Full Name</b></td><td>Mitochondrial Arginyl-tRNA Synthetase 2</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>2q33.1</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>[92935](https://www.ncbi.nlm.nih.gov/gene/92935)</td></tr>
<tr><td><b>OMIM</b></td><td>[609446](https://www.omim.org/entry/609446)</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000135953</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q9N3W4](https://www.uniprot.org/uniprot/Q9N3W4)</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Spastic Paraplegia (SPG74), [ALS](/diseases/amyotrophic-lateral-sclerosis), [Parkinson's Disease](/diseases/parkinsons-disease), Mitochondrial Disorders</td></tr>
</table>
</div>

Overview

MARS2 (Mitochondrial Arginyl-tRNA Synthetase 2) encodes a mitochondrial aminoacyl-tRNA synthetase (mtARS) that specifically charges arginine to its cognate mitochondrial tRNA. Mitochondrial aminoacyl-tRNA synthetases are essential enzymes that catalyze the attachment of amino acids to their respective tRNA molecules, a critical step in mitochondrial protein synthesis. These enzymes are distinct from their cytosolic counterparts and are encoded by nuclear genes but function within the mitochondrial matrix. MARS2 is one of several mtARS genes linked to neurodegenerative diseases, including hereditary spastic paraplegia (HSP) and amyotrophic lateral sclerosis (ALS). Mutations in MARS2 cause autosomal recessive hereditary spastic paraplegia type 74 (SPG74), characterized by progressive lower limb spasticity and mitochondrial dysfunction. The enzyme's role in maintaining mitochondrial translation makes it critical for neuronal survival, particularly in long projection neurons that are affected in HSP and ALS[@sissler2017][@antonellis2019].

Summary

MARS2 encodes mitochondrial arginyl-tRNA synthetase 2, a nuclear-encoded enzyme that functions in the mitochondrial matrix to charge arginine to mitochondrial tRNA. This enzymatic function is essential for the translation of the 13 oxidative phosphorylation (OXPHOS) proteins encoded by mitochondrial DNA. MARS2 mutations cause autosomal recessive hereditary spastic paraplegia type 74 (SPG74), presenting with progressive spasticity and gait disturbance. The disease mechanism involves impaired mitochondrial translation leading to OXPHOS deficiency, reduced ATP production, and increased susceptibility to oxidative stress. Given the high energy demands of neurons, particularly long axonal projection neurons, mitochondrial translation defects have profound consequences for neuronal viability. MARS2 represents one of several mtARS genes implicated in neurodegeneration, highlighting the importance of mitochondrial protein synthesis for neuronal health[@beyer2019][@bayat2017].

Normal Function

Enzymatic Activity

MARS2 catalyzes the aminoacylation reaction:

L-arginine + tRNA(Arg) + ATP → Arg-tRNA(Arg) + AMP + PPi

This reaction occurs in the mitochondrial matrix and is essential for mitochondrial translation.

Protein Structure

Human MARS2 protein properties:

• Length: Approximately 577 amino acids
• Molecular weight: ~65 kDa
• Domains: Contains the catalytic domain typical of class I aminoacyl-tRNA synthetases
• Mitochondrial targeting: N-terminal mitochondrial targeting peptide (MTS)

Mitochondrial Translation

MARS2 functions in mitochondrial translation:

Disease Associations

Hereditary Spastic Paraplegia Type 74 (SPG74)

MARS2 mutations cause autosomal recessive HSP:

Amyotrophic Lateral Sclerosis (ALS)

MARS2 is implicated in ALS:

Parkinson's Disease

Mitochondrial translation defects in PD:

Expression Pattern

Tissue Distribution

MARS2 is expressed in tissues with high mitochondrial energy demands:

• Brain: Cortex, hippocampus, basal ganglia, spinal cord
• Heart: High expression in cardiac muscle
• Skeletal muscle: High expression in muscle fibers
• Liver: Substantial expression in hepatocytes
• Kidney: Renal tubular cells

Cellular Expression

In the nervous system:

• Neurons: High expression in pyramidal neurons and motor neurons
• Astrocytes: Moderate expression
• Oligodendrocytes: Important for myelin production
• Microglia: Lower expression

Interaction Network

| Partner | Relationship | Function |
|---------|--------------|----------|
| Mitochondrial ribosome | Component | Site of mitochondrial translation |
| mtDNA-encoded proteins | Product | OXPHOS complex subunits |
| Mitochondrial tRNA(Arg) | Substrate | Substrate for aminoacylation |
| ATP | Energy source | Required for aminoacylation |
| Other mtARS enzymes | Partner | Coordinated mitochondrial translation |

Therapeutic Approaches

Small Molecule Strategies

Gene Therapy

• Viral vector delivery of wild-type MARS2
• CRISPR-based correction of pathogenic variants

Supportive Care

• Physical therapy for spasticity
• Occupational therapy
• Assistive devices for mobility

Animal Models

Zebrafish Models

Zebrafish studies show:

• Morpholino knockdown causes motor defects
• Mitochondrial dysfunction in neural tissues
• Axonal pathfinding abnormalities

Mouse Models

• Mars2 knockout: Embryonic or early postnatal lethal
• Conditional knockouts: Tissue-specific deletion reveals neuronal functions

Molecular Mechanisms

Mitochondrial Translation Defects

MARS2 mutations impair mitochondrial translation through several mechanisms[@martin2019]:

OXPHOS Dysfunction

The resulting OXPHOS deficiency has multiple consequences:

• Complex I deficiency: Most commonly affected
• Complex III and IV: Secondary effects
• ATP depletion: Insufficient energy for cellular functions
• ROS overproduction: Electron leak from damaged complexes

Neuronal Vulnerability

Why are neurons particularly susceptible[@wallace2018]:

Mechanism Diagram

Genetic Basis

SPG74 Mutations

MARS2 mutations causing hereditary spastic paraplegia[@eskier2018]:

| Mutation Type | Frequency | Effect |
|--------------|-----------|--------|
| Nonsense | Common | Truncated protein |
| Frameshift | Common | Premature stop |
| Splice-site | Less common | Exon skipping |
| Missense | Rare | Partial loss |

Genotype-Phenotype Correlation

• Biallelic null mutations → severe SPG74
• Missense variants → variable presentation
• Compound heterozygosity → intermediate severity

Clinical Features

Hereditary Spastic Paraplegia Type 74

Core Features:

• Progressive lower limb spasticity
• Gait disturbance
• Lower limb weakness
• Hyperreflexia

• Intellectual disability
• Peripheral neuropathy
• Optic atrophy
• Seizures (rare)

Age of Onset

• Childhood to early adulthood
• Typically before age 20
• Progressive course over decades

Diagnostic Approach

Biochemical Testing

Genetic Testing

Differential Diagnosis

• Other forms of HSP (SPG4, SPG5, etc.)
• Primary lateral sclerosis
• Hereditary ataxias
• Mitochondrial disorders

Therapeutic Strategies

Current Approaches

Symptomatic:

• Spasticity management (baclofen, tizanidine)
• Physical therapy
• Orthopedic interventions
• Assistive devices

• CoQ10 supplementation
• Lipoic acid
• Vitamin supplementation

Investigational Therapies

Mitochondrial Modulation:

• Small molecules enhancing mitochondrial function
• Antioxidants targeting mitochondrial ROS
• ATP supplementation strategies

• Viral vector delivery of wild-type MARS2
• CRISPR-based gene editing
• mRNA delivery for protein expression

Comparison with Other mtARS Genes

| Gene | Protein | Associated Diseases |
|------|---------|-------------------|
| MARS2 | Mitochondrial Arg-tRNA synthetase 2 | SPG74, ALS |
| RARS2 | Mitochondrial Arg-tRNA synthetase | Pontocerebellar hypoplasia |
| DARS2 | Mitochondrial Asp-tRNA synthetase | Leukoencephalopathy |
| EARS2 | Mitochondrial Glu-tRNA synthetase | LTBL |
| PARS2 | Mitochondrial Pro-tRNA synthetase | Epilepsy |

Research Models

Cellular Models

• Patient fibroblasts: Show OXPHOS defects
• iPSC-derived neurons: Model disease mechanisms
• CRISPR-edited cells: Isogenic controls

Animal Models

• Zebrafish: Morpholino knockdowns, motor phenotype
• Drosophila: Homolog studies
• Mouse: Conditional knockouts

Key Publications

Pathophysiology in Detail

Energy Crisis in Long Axons

The corticospinal tract neurons affected in HSP have exceptionally long axons that connect the motor cortex to the spinal cord. These axons span up to a meter in humans and require massive amounts of ATP for:

When MARS2 mutations impair mitochondrial translation, ATP production falls below the threshold required to maintain these functions, leading to axonal degeneration beginning at the distal ends[@turner2015].

Oxidative Stress Cascade

Impaired mitochondria generate increased reactive oxygen species:

Compensatory Mechanisms

Cells attempt to compensate for mitochondrial dysfunction:

These mechanisms eventually fail as dysfunction progresses.

Disease Progression

Early Stage

• Mild gait disturbance
• Subtle spasticity
• Normal activities possible

Middle Stage

• Progressive spasticity
• Gait difficulties requiring aids
• Lower limb weakness
• Fatigability

Late Stage

• Severe spasticity
• Wheelchair dependence
• Contractures
• Potential complications (UTIs, pneumonia)

Management Guidelines

Multidisciplinary Care

Spasticity Management

• Oral medications: Baclofen, tizanidine, benzodiazepines
• Botulinum toxin: Focal injections
• Intrathecal baclofen: For severe cases
• Surgical: Tenotomy for contractures

Surveillance

• Regular neurological assessment
• Gait analysis
• Pulmonary function (if severe)
• Developmental assessment (children)

Research Directions

Biomarker Development

Therapeutic Targets

Clinical Trials

• No MARS2-specific trials yet
• Trials of CoQ10 and mitochondrial supplements
• Trials of gene therapy for other mtARS disorders

Animal Model Insights

Zebrafish Studies

Zebrafish provide valuable insights[@bayat2017]:

• Morpholino knockdown: Recapitulates human phenotype
• Motor defects: Swimming abnormalities
• Mitochondrial dysfunction: Complex I deficiency
• Axonal defects: Peripheral nerve abnormalities
• Rescue studies: Show proof-of-concept for therapy

Therapeutic Rescue

• Mitochondrial supplements partially rescue phenotype
• Gene expression restoration possible
• Early intervention more effective

Neuroimaging Findings

MRI Patterns

Advanced Imaging

• DTI: Shows white matter tract damage
• MRS: Elevated lactate in some cases
• Functional MRI: Altered connectivity

Prognosis

Life Expectancy

• Normal life expectancy in isolated HSP
• Reduced in complex phenotypes
• Variable based on mutation severity

Quality of Life

• Impact varies with disease severity
• Early intervention improves outcomes
• Supportive care essential

Prevention

Genetic Counseling

• Autosomal recessive inheritance
• 25% recurrence risk for carrier parents
• Testing available for at-risk family members
• Preimplantation genetic diagnosis possible

Prenatal Testing

• Available for confirmed pathogenic variants
• Allows informed family planning

Conclusion

MARS2 mutations cause hereditary spastic paraplegia type 74 through impaired mitochondrial translation and resulting OXPHOS deficiency. The disease primarily affects long corticospinal tract axons, leading to progressive spasticity and gait disturbance. Understanding the molecular mechanisms has identified potential therapeutic targets, though effective treatments remain to be developed. Genetic counseling is essential for affected families.

Related Conditions

• [Hereditary spastic paraplegia](/diseases/hereditary-spastic-paraplegia)
• [Amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Parkinson's disease](/diseases/parkinsons-disease)
• [Mitochondrial disorders](/diseases/mitochondrial-disorders)
• [Mitochondrial translation](/mechanisms/mitochondrial-translation)
• [OXPHOS dysfunction](/mechanisms/oxphos-dysfunction)

See Also

• [Genes Directory](/genes/)
• [Proteins Directory](/proteins/)
• [Aminoacyl-tRNA synthetases](/mechanisms/aminoacyl-trna-synthetases)
• [Mitochondrial protein synthesis](/mechanisms/mitochondrial-protein-synthesis)

External Links

• [NCBI Gene: MARS2](https://www.ncbi.nlm.nih.gov/gene/92935)
• [Ensembl: ENSG00000135953](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000135953)
• [UniProt: Q9N3W4](https://www.uniprot.org/uniprot/Q9N3W4)
• [OMIM: 609446](https://www.omim.org/entry/609446)